Hikal Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations'.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited has disclosed that its Jigani (Bangalore) facility received a Warning Letter from the USFDA on August 21, 2025, following an inspection conducted in February 2025. The inspection resulted in six Form 483 observations, and the USFDA had earlier classified the site as 'Official Action Intended' (OAI) in May 2025. The Warning Letter cites inadequate investigations of customer complaints regarding foreign matter and shortcomings in vendor management. No monetary penalty, import restriction, or sanction has been imposed. Hikal responded to the Warning Letter on September 11, 2025, with corrective actions, many of which are already in place, and is working closely with the USFDA to resolve the concerns. The company has flagged potential revenue delays from the first half of the financial year shifting to the second half.
The Warning Letter signals a regulatory overhang on Hikal's Jigani operations, with expected revenue timing delays and uncertainty around when a USFDA reinspection and clearance will occur. Near-term stock sentiment may be pressured, though the absence of any import alert or restriction and the company's proactive corrective response limit the risk of a deeper impact.